Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Vismodegib therapy effective against medulloblastoma

Vismodegib therapy effective against medulloblastoma

Endocrine Society recommends removal of tumor as first-line treatment for endogenous Cushing's syndrome

Endocrine Society recommends removal of tumor as first-line treatment for endogenous Cushing's syndrome

Study points to new treatment strategies for liver cancer

Study points to new treatment strategies for liver cancer

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Researchers identify genetic abnormalities that lead to skin SCC

Researchers identify genetic abnormalities that lead to skin SCC

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Researchers map physical properties of live breast cancer cells using advanced AFM technology

Researchers map physical properties of live breast cancer cells using advanced AFM technology

dlDNA marks progression of HBV-related liver disease

dlDNA marks progression of HBV-related liver disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.